News
Oral GLP-1 pill matches dapagliflozin on blood sugar in an 810-person phase 3 trial in China
AI-assisted summary Written by WellCareChina with AI assistance and checked against the original article.
A phase 3 trial published in Nature Medicine on 5 October 2026 compared safiglipron, an oral small-molecule GLP-1 receptor agonist taken without fasting or dietary restrictions, with dapagliflozin in 810 adults with type 2 diabetes at 98 sites in China. After 32 weeks the fall in HbA1c with safiglipron was non-inferior to dapagliflozin at all three doses tested (30, 60 and 90 mg), and the 90 mg dose also met the pre-set criterion for superiority in a secondary analysis. The study continued with a 20-week extension; longer-term results are not yet reported.
Read the original article Opens the original source in a new tab.
Copyright and re-use
The original article is the authoritative text. This page carries our own summary and a link back; no part of the original is reproduced here.
Source tier A — open-access article (CC BY 4.0); our own summary and a link back to the original, no full-text copy.